AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors
June 01 2021 - 4:01PM
AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a
regenerative medicine company that is developing and
commercializing a technology platform that enables point-of-care
autologous skin restoration for multiple unmet needs, announced
today the appointment of James Corbett and Jan Stern Reed to its
Board of Directors effective July 1, 2021.
Mr. Corbett has approximately 40 years of
leadership experience in the medical device field, most recently,
as CEO of CathWorks Ltd., a software-based medical technology
company. Mr. Corbett has extensive global commercial and operating
experience, serving as an expatriate General Manager of Baxter
Japan and later as General Manager and President of Scimed Life
Systems Inc. and Boston Scientific International respectively.
During his career he has served as CEO of 3 publicly listed
companies; Microtherapeutics Inc (MTIX), ev3 Inc (evvv), Alphatec
Spine (ATEC). Mr. Corbett has also led two privately funded
companies as CEO; Home Diagnostics Inc. and Vertos Medical. Mr.
Corbett has extensive capital market and governance experience from
both public and private environments. Mr. Corbett holds a Bachelor
of Science in Business Administration from the University of
Kansas.
Ms. Reed has more than 35 years of legal,
management and business leadership experience primarily within the
healthcare industry, and brings significant expertise in corporate
governance, compliance and risk management. Most recently, she was
Senior Vice President, General Counsel and Corporate Secretary at
Walgreens Boots Alliance, Inc., a global pharmacy-led, health and
wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice
President, Human Resources, General Counsel and Corporate Secretary
of Solo Cup Company, where she was responsible for the legal, human
resources, internal audit, corporate communications, and compliance
functions. Prior to Solo Cup Company, she was Associate General
Counsel, Corporate Secretary and Chief Corporate Governance Officer
at Baxter International, Inc.. Ms. Reed currently serves as a board
member of Stepan Co. (NYSE:SCL) and AngioDynamics, Inc. (NASDAQ:
ANGO). Ms. Reed holds a Bachelor of Arts degree with honors in
Psychology from the University of Michigan and a Juris Doctor from
the Northwestern University Pritzker School of Law.
“We are delighted by the addition of James and Jan to our Board
of Directors. They will further strengthen our Board, bringing
extensive medical device commercialization, legal and strategic
business expertise to Avita,” said Lou Panaccio, Chairman of the
Board of Avita Medical. “We look forward to leveraging James’
experience in running global medical device commercialization
efforts as we continue to build market share in burns and beyond,
and we expect Jan’s breath of executive leadership experience will
be invaluable as we continue to execute on our myriad growth
objectives.”
About AVITA Medical, Inc.:
AVITA Medical is a regenerative medicine company
with a technology platform positioned to address unmet medical
needs in burns, chronic wounds, and aesthetics indications. AVITA
Medical’s proprietary collection and application technology
provides innovative treatment solutions derived from the
regenerative properties of a patient’s own skin. The medical
devices work by preparing a RES® REGENERATIVE EPIDERMAL
SUSPENSION, an autologous suspension comprised of the patient’s
skin cells necessary to regenerate natural healthy epidermis. This
autologous suspension is then sprayed onto the areas of the patient
requiring treatment.
AVITA Medical’s first U.S. product, the
RECELL® System, was approved by the U.S. Food and Drug
Administration (FDA) in September 2018. The RECELL System is
indicated for use in the treatment of acute thermal burns in
patients 18 years and older. The RECELL System is used to prepare
Spray-On Skin™ Cells using a small amount of a patient’s own skin,
providing a new way to treat severe burns, while significantly
reducing the amount of donor skin required. The RECELL System is
designed to be used at the point of care alone or in combination
with autografts depending on the depth of the burn injury.
Compelling data from randomized, controlled clinical trials
conducted at major U.S. burn centers and real-world use in more
than 10,000 patients globally, reinforce that the RECELL System is
a significant advancement over the current standard of care for
burn patients and offers benefits in clinical outcomes and cost
savings. Healthcare professionals should read the INSTRUCTIONS FOR
USE - RECELL® Autologous Cell Harvesting Device for a full
description of indications for use and important safety information
including contraindications, warnings and precautions.
In international markets, our products are
marketed under the RECELL System brand to promote skin healing in a
wide range of applications including burns, chronic wounds and
aesthetics. The RECELL System is TGA-registered in Australia and
received CE-mark approval in Europe.
For Further Information:
U.S. MediaSam Brown, Inc. Christy CurranPhone
+1-615-414-8668christycurran@sambrown.com |
InvestorsWestwicke PartnersCaroline Corner Phone
+1-415-202-5678caroline.corner@westwicke.com |
|
|
O.U.S. MediaRudi Michelson Phone +61 (0)3 9620
3333Mobile +61 (0)411 402 737rudim@monsoon.com.au |
|
Stepan (NYSE:SCL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Stepan (NYSE:SCL)
Historical Stock Chart
From Oct 2023 to Oct 2024